Edwards Lifesciences said it appointed Theodora Mistras as Corporate Vice President, Chief Financial Officer, effective May 29, 2026, succeeding Scott B. Ullem in the role. The announcement was made on May 4, 2026.

1. 01

   Edwards Lifesciences said it appointed Theodora Mistras as Corporate Vice President, Chief Financial Officer, effective May 29, 2026, succeeding Scott B. Ullem in the role. The announcement was made on May 4, 2026.

2. 02

   The company said Mistras has served as Chief Financial Officer of Viatris, Inc. since March 1, 2024, and previously served as Managing Director, Healthcare Investment Banking at Citigroup Global Markets and Goldman Sachs.

3. 03

   Under the Offer Letter, the company will pay Mistras a base salary of $925,000 a year, with a target annual bonus of not less than 100% of her then-current base salary, and a sign-on bonus of $2,013,000 paid promptly after her start date.

4. 04

   The company said it will grant Mistras restricted stock units with a grant date value of $8,000,000, vesting 43.75% on the 1st anniversary of her start date, 50% on the 2nd anniversary and 6.25% on the 3rd anniversary, in each case subject to her continued employment.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.